December 23, 2014
October 14, 2014
Barcelona, 14 October 2014 – GAPCAV Consortium announces today that they are moving a novel concept of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC), into the clinic. The German national authority, the Paul-Ehrlich-Institute (PEI), has approved the start of a phase 1/2 study, GAPVAC-101, which applies for the first time the concept of treating glioblastoma patients based on peptide drugs designed and manufactured for each patient individually according to specific characteristics of their tumor and immune system.GAPVAC Press Release Oct 14
May 5, 2014
It is a pleasure to inform that BCN Peptides, S.A has renewed its ISO9001:2008 certification after being audited by the correspondent certification body. BCN Peptides, S.A was certified for the first time for ISO9001 on 1999. This certification includes the manufacturing and new product design operations.
On the other side, BCN Peptides S.A. has obtained, for the first time, the ISO14001 certification. As in the previous case, this certification not only includes the production operations but also the new products design.
April 11, 2014
BCN Peptides has been successfully inspected by Catalan Health Authorities (on behalf of the AEMPS- Spanish Health Agency), for the Manufacture and Release of Peptides and Sterile Peptide. After this inspection, the GMP certificate was immediately renewed.